Showing 1311-1320 of 2942 results for "".
- Potassium Channel Modulator Reduces Focal Onset Seizure Frequency in Clinical Trialshttps://practicalneurology.com/news/potassium-channel-modulator-reduces-focal-onset-seizure-frequency-in-clinical-trials/2469954/In the phase 2b X-TOLE trial, participants ( treated with the positive allosteric modulator of the KCNQ2/3 (Kv7.2/7.3) potassium channel (XEN1101; Xenon Pharmaceuticals, Burnaby, British Columbia) had significant reduction in the frequency of focal onset seizures. Seizure reductions occurred as e
- Rapid and Sustained Seizure Termination With Midazolam in Open-Label Extension Studyhttps://practicalneurology.com/news/rapid-and-sustained-seizure-termination-with-midazolam-in-open-label-extension-study/2469769/Post hoc analysis of an open-label extension study (NCT01529034) showed treatment with midazolam nasal spray (Nayzilam; UCB Pharma, Smyrna, GA) terminated 92% of seizure cluster episodes. There was no seizure recurrence from 10 minutes of treatment to 24 hours for 85% of treated seizure cluster e
- Phase 2b Study Ending for Sublingual Ketamine for Acute Painhttps://practicalneurology.com/news/phase-2b-study-ending-for-sublingual-ketamine-for-acute-pain/2468909/The Food and Drug Administration (FDA) has scheduled an end-of-phase 2 clinical trial meeting for a sublingual formulation of racemic ketamine (Wafermine; iX Biopharma, Singapore) for treatment of moderate-to-severe acute pain. The therapy contains R and S isomers of ketamine in e
- Research Leaders Recognized at the 2025 MDA Clinical & Scientific Conferencehttps://practicalneurology.com/news/research-leaders-recognized-at-the-2025-mda-clinical-scientific-conference/2473814/The Muscular Dystrophy Association (MDA) recognized 2 legacy award recipients at the 2025 MDA Clinical & Scientific Conference. The awardees were honored based on their significant contributions to clinical research and community advocacy. The 2025 MDA Legacy Award for Achie
- MDA Provides COVID-19 Recommendations for People with Neuromuscular Conditions that Also Apply to Other Neurologic Conditionshttps://practicalneurology.com/news/mda-provides-covid-19-recommendations-for-people-with-neuromuscular-conditions-that-also-apply-to-other-neurologic-conditions/2469188/The Muscular Dystrophy Association (MDA) has provided recommendations for people in the neuromuscular community regarding the current COVID-19 pandemic. Noting that current guidelines from public health agencies focus on travelers, specific age group
- FDA Rejects Application for Gene Therapy for Hunter Syndromehttps://practicalneurology.com/news/fda-rejects-application-for-gene-therapy-for-hunter-syndrome/2485648/The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for RGX-121 (clemidsogene lanparvovec; REGENXBIO, Rockville, MD), meaning that, at this time, the FDA will not approve the investigational gene therapy for mucopolysaccha
- Director of the National Institute of Neurological Disorders and Stroke Oustedhttps://practicalneurology.com/news/director-of-the-national-institute-of-neurological-disorders-and-stroke-ousted/2485145/The contract for Walter Koroshetz, MD, as Director of the National Institute of Neurological Disorders and Stroke (NINDS) has not been renewed, ending his leadership of the institute after 10 years. Dr. Koroshetz’s departure comes despite a positive internal review and a recommendation for reappo
- Prof. Ludwig Kappos Recognized for His Lifetime Achievement in Multiple Sclerosis Research at ECTRIMS 2025https://practicalneurology.com/news/prof-ludwig-kappos-recognized-for-his-lifetime-achievement-in-multiple-sclerosis-research-at-ectrims-2025/2483561/At the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Ludwig Kappos, MD, Dipl Psych, FEAN, FAAN was recognized as the recipient of the 2025 Charcot Award. According to ECTRIMS, the Charcot Award, which is presented by the Multiple Sclerosis Int
- Studies Evaluate the Reweighting of Parkinson Disease Assessment Tools for Improved Sensitivity and Efficiencyhttps://practicalneurology.com/news/studies-evaluate-the-reweighting-of-parkinson-disease-assessment-tools-for-improved-sensitivity-and-efficiency/2474181/Reweighting the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and other measures may provide greater sensitivity and responsiveness in assessing motor and functional decline in people with Parkinson disease (PD), according to the results of 2 studies presented at
- Continuous, Subcutaneous Apomorphine Infusion Device Approved for Parkinson’shttps://practicalneurology.com/news/continuous-subcutaneous-apomorphine-infusion-device-approved-for-parkinsons/2473778/The Food and Drug Administration (FDA) has approved the wearable Onapgo (apomorphine hydrochloride; Supernus Pharmaceuticals, Rockville, MD) subcutaneous injection device to treat motor fluctuations in adults with advanced Parkinson disease (PD). Onapgo enables continuous apomorphine infusion dur